Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R R Wenzel

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Clinical Nephrology|March 1, 2003
A new system for regional citrate anticoagulation in continuous venovenous hemodialysis (CVVHD)A Mitchell, A E Daul, M Beiderlinden, et al.
Journal of Cardiovascular Pharmacology|September 7, 2000
Systemic, pulmonary, and renal hemodynamic effects of endothelin ET(A/B)-receptor blockade in patients with maintained left ventricular functionM Fleisch, G Sütsch, X W Yan, et al.
Circulation|November 24, 1998
Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery diseaseR R Wenzel, M Fleisch, S Shaw, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Clinical Nephrology|March 1, 2003
A new system for regional citrate anticoagulation in continuous venovenous hemodialysis (CVVHD)A Mitchell, A E Daul, M Beiderlinden, et al.
Journal of Cardiovascular Pharmacology|September 7, 2000
Systemic, pulmonary, and renal hemodynamic effects of endothelin ET(A/B)-receptor blockade in patients with maintained left ventricular functionM Fleisch, G Sütsch, X W Yan, et al.
Circulation|November 24, 1998
Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery diseaseR R Wenzel, M Fleisch, S Shaw, et al.
Pageof 5